Investors & Media
Abstract Number: 3038
Implications of DYRK1B kinase in ovarian cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for ovarian cancers
Session: Drug Resistance 4
Date and Time: Tuesday April 2, 2019; 8:00 a.m. - 12:00 p.m. EDT
Location: Exhibit Hall B; Poster Section 12; Poster Board Number 30
How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL.
DYRK1B inhibitors prevent pharmacologic quiescence and sensitize lung cancers to EGFR inhibitors.
Date and Time: January 13th 2016 8AM
Location: The Parc 55 San Francisco Track A